Clinical Trial Update: Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and preliminary efficacy of combining selumetinib with standard first-line therapy in locally advanced or metastatic non-small c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: AstraZeneca | Conditions: Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV | Phase 1 | Status: COMPLETED | Results posted: 2018-03-13